Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury.

Abstract

Cisplatin is an established chemotherapeutic drug for treatment of solid-organ cancers and is the primary drug used in the treatment of head and neck cancer; however, cisplatin-induced nephrotoxicity largely limits its clinical use. Inhibition of sphingosine kinase 2 (SphK2) has been demonstrated to alleviate various kidney diseases. Therefore, we hypothesized that inhibition of SphK2 could also protect against cisplatin-induced nephrotoxicity. Results from the present study showed that the SphK2 inhibitor ABC294640 or knockdown of SphK2 by siRNA blocked the cisplatin-induced increase of cellular injury markers (neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, and cleaved caspase-3) by Western blot analysis in HK-2 cells, a human renal tubular cell line. In addition, SphK2 inhibition blocked cisplatin-induced activation of NF-κB by Western blot analysis and immunostaining analysis. Furthermore, SphK2 inhibition suppressed cisplatin-induced increases of proinflammatory markers (NLR family pyrin domain containing 3, interleukin-1β, and interleukin-6). Genetic deletion of the SphK2 gene in mice further confirmed that inhibition of SphK2 protected against cisplatin-induced kidney damage in vivo. Compared with wild-type mice, SphK2 knockout mice exhibited less renal dysfunction and reduced promotion of kidney injury markers, inflammatory factors, tubular morphology damage, and fibrotic staining. At the same time, the SphK2 inhibitor ABC294640 failed to interfere with the activity of cisplatin or radiation in two cell culture models of head and neck cancer. It is concluded that inhibition of Sphk2 protects against cisplatin-induced kidney injury. SphK2 may be used as a potential therapeutic target for the prevention or treatment of cisplatin-induced kidney injury.NEW & NOTEWORTHY The present study provides new findings that sphingosine kinase 2 (SphK2) is highly expressed in renal tubules, cisplatin treatment increases the expression of SphK2 in proximal tubular cells and kidneys, and inhibition of SphK2 alleviates cisplatin-induced kidney injury by suppressing the activation of NF-κB, production of inflammatory factors, and apoptosis. SphK2 may serve as a potential therapeutic target for the prevention or treatment of cisplatin-induced nephrotoxicity.

• Authors: Dengpiao Xie, Gaizun Hu, Chaoling Chen, Fereshteh Ahmadinejad, Weili Wang, Pin-Lan Li, David A Gewirtz, Ningjun Li
• Journal: American journal of physiology. Renal physiology (Am J Physiol Renal Physiol) Vol. 323 Issue 3 Pg. F322-F334 (09 01 2022) ISSN: 1522-1466 [Electronic] United States
• PMID: 35834271 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• NF-kappa B
• Phosphotransferases (Alcohol Group Acceptor)
• sphingosine kinase 2, mouse
• sphingosine kinase 2, human
• Cisplatin

Topics

• Acute Kidney Injury (chemically induced, genetics, prevention & control)
• Animals
• Apoptosis
• Cisplatin (adverse effects)
• Humans
• Kidney (metabolism)
• Mice
• Mice, Inbred C57BL
• NF-kappa B (metabolism)
• Phosphotransferases (Alcohol Group Acceptor) (genetics)